Eli Lilly's Xigris Linked to Severe Bleeding
A recent article in the NY Times highlighted the problems surrounding Eli Lilly's sepsis drug Xigris. The drug, which costs $8000 for a four day treatment, is considered to be no more effective than other, much less expensive drug. Further, Lilly halted two clinical trials when results indicated a higher risk of severe, life-threatening bleeding.
Approved in 2001, Lilly heavily marketed Xigris to hospitals and doctors, using questionable science to back up the claims made in the marketing.
Approved in 2001, Lilly heavily marketed Xigris to hospitals and doctors, using questionable science to back up the claims made in the marketing.
Post A Comment / Question